Cells (Apr 2021)

Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease

  • Camille Boisson,
  • Minke A. E. Rab,
  • Elie Nader,
  • Céline Renoux,
  • Celeste Kanne,
  • Jennifer Bos,
  • Brigitte A. van Oirschot,
  • Philippe Joly,
  • Romain Fort,
  • Alexandra Gauthier,
  • Emeric Stauffer,
  • Solene Poutrel,
  • Kamila Kebaili,
  • Giovanna Cannas,
  • Nathalie Garnier,
  • Cécile Renard,
  • Olivier Hequet,
  • Arnaud Hot,
  • Yves Bertrand,
  • Richard van Wijk,
  • Vivien A. Sheehan,
  • Eduard J. van Beers,
  • Philippe Connes

DOI
https://doi.org/10.3390/cells10040811
Journal volume & issue
Vol. 10, no. 4
p. 811

Abstract

Read online

(1) Background: The aim of the present study was to compare oxygen gradient ektacytometry parameters between sickle cell patients of different genotypes (SS, SC, and S/β+) or under different treatments (hydroxyurea or chronic red blood cell exchange). (2) Methods: Oxygen gradient ektacytometry was performed in 167 adults and children at steady state. In addition, five SS patients had oxygenscan measurements at steady state and during an acute complication requiring hospitalization. (3) Results: Red blood cell (RBC) deformability upon deoxygenation (EImin) and in normoxia (EImax) was increased, and the susceptibility of RBC to sickle upon deoxygenation was decreased in SC patients when compared to untreated SS patients older than 5 years old. SS patients under chronic red blood cell exchange had higher EImin and EImax and lower susceptibility of RBC to sickle upon deoxygenation compared to untreated SS patients, SS patients younger than 5 years old, and hydroxyurea-treated SS and SC patients. The susceptibility of RBC to sickle upon deoxygenation was increased in the five SS patients during acute complication compared to steady state, although the difference between steady state and acute complication was variable from one patient to another. (4) Conclusions: The present study demonstrates that oxygen gradient ektacytometry parameters are affected by sickle cell disease (SCD) genotype and treatment.

Keywords